Mega IgG2000 Powder
Mega IgG2000 Capsules
Mega IgG2000 is a dairy-free immunoglobulin concentrate that supports healthy digestion and maintains healthy gut barrier function. Unlike other milk-derived immunoglobulins on the market, Mega IgG2000 is derived from bovine serum, making it lactose-free, casein-free, and β-lactoglobulin-free.
How to buy?
A valid Practitioner account is required for direct purchases from our website. Let’s get you registered!
What is MegaIgG2000?
Mega IgG2000 is a dairy-free immunoglobulin concentrate that supports healthy digestion, detoxification, and gut barrier function. Unlike other milk-derived immunoglobulins on the market, Mega IgG2000 is derived from bovine serum, making it lactose-free, casein-free, and β-lactoglobulin-free.
This unique alternative to bovine colostrum supports a healthy mucosal immune system by maintaining healthy gut barrier function. The serum immunoglobulin in Mega IgG2000 has been the subject in over 10 published human clinical trials.*
Dosing Instructions
Ages 2+. Take 4 capsules daily with or without a meal, or as directed by your healthcare professional.
Learn More About
Mega IgG2000™
Immune Support Studies:
|
Form/ Duration |
Study Details and Results |
References |
|
Mega IgG2000 2 weeks |
In a randomized, double-blind, placebo-controlled, pilot study evaluating SBI in children 8-18 y with d-IBS, we collected stool number, abdominal pain, and stool type for 1 wk. We assigned patients at a ratio of 2:1 to SBI 5 gm BID or placebo for 3 wk. Patients and parents completed Pediatric Quality of Life Inventory for Gastrointestinal Symptoms (PedsQOL), the Pediatric Functional Disability Index (FDI), complete blood counts and serum chemistries at the start and end of treatment. Fifteen patients (9 SBI, 6 placebo) completed the study. Both groups reported reductions in stools/wk and abdominal pain, and improved stool form. There was a trend for fewer stools in the SBI group compared to placebo. FDI and PedsQOL scores improved.in the SBI group, but not placebo. No serious adverse events occurred. SBI was safe in children with d-IBS, with improvement in symptoms. |
Proliant Health (2016). EnteraGam: Managing Gastrointestinal Conditions While Not Harming Beneficial Bacteria [White Paper] |
| Mega IgG2000
duration and dose unspecified |
White Paper- Summary Immunoglobulins in SBI have been shown to bind to a variety of conserved microbial antigens that are associated with immune activation (e.g. LPS, flagellin). Commensal-specific immunoglobulins (e.g. IgG, IgM, IgA) occur naturally in both plasma and the gastrointestinal tract. Preclinical studies demonstrate that SBI does not adversely affect the growth of commensal & probiotic bacteria in vitro or cause changes in the intestinal microbiota in an animal model used to evaluate host-microbiota relationships. Data from human studies indicate no significant changes in commensal microflora following oral administration of EnteraGam. Commensal-specific immunoglobulins likely provide a health benefit by supporting gut homeostasis and immune regulation activation. |
DOI: doi.org/10.1111/hel.12856 |
(continued):
|
Form/ Duration |
Study Details and Results |
References |
|
Mega IgG2000 |
Serum‐derived bovine immunoglobulin (SBI) is a protein isolate rich in immunoglobulins for oral administration to improve immune health. SBI reduces inflammation by binding and neutralizing a variety of inflammatory antigens, improving gut epithelial barrier integrity, and maintaining gut homeostasis. In this study, fluorescence spectroscopy was used to demonstrate and quantify the binding of SBI to the fungal mycotoxins, aflatoxin G1 (AFG1) and aflatoxin B2 (AFB2). Calculated binding constants reveal SBI binds with both AFG1 and AFB2 in a dose dependent manner, likely through immunoglobulin‐aflatoxin interactions. |
Proliant Health (2023). Mycotoxin Binding to SBI and Bovine Immunoglobulins [White Paper] |
| Mega IgG2000
5g, ex-vivo study |
When dosed at an equivalent of 5 g/day, all protein fractions significantly increased health-related metabolites—acetate, propionate, and butyrate. Upon simulating small intestinal absorption, SBI still markedly increased acetate and propionate, demonstrating that SBI is more resistant to small intestinal digestion and absorption compared to the other protein sources. |
DOI: 10.3390/microorganisms11030659 |
